Advertisement

Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review

  • Michele PorcuEmail author
  • Cinzia Solinas
  • Cristina Migali
  • Angelo Battaglia
  • Marina Schena
  • Lorenzo Mannelli
  • Alfredo Addeo
  • Karen Willard-Gallo
  • Luca Saba
Review Article

Abstract

The immunotherapy revolution in cancer treatment involves a variety of specialists, not only oncologists, but also internal medicine physicians, endocrinologists, dermatologists, gastroenterologists, rheumatologists, and radiologists, introducing new scenarios and novel challenges in the diagnosis and management of a number of novel immune-related adverse events. Among these, immune checkpoint inhibitor-induced pancreatic injury has been described (occurring in up to 4% of patients) and has been reported to be responsible for visits to the emergency departments in up to 1.9% of patients treated with immune checkpoint inhibitors. This side effect can be symptomatic or non-symptomatic, and can be associated with the development of long-term damage to the pancreas, requiring the involvement of different specialists, including radiologists and gastroenterologists in the multidisciplinary team that manages these patients. The aim of this narrative review is to provide a summary of the available literature related to immune checkpoint inhibitor-induced pancreatic injury including the epidemiology, the clinical findings, and the management algorithm for diagnosis with a detailed analysis of the differential diagnosis at imaging, and treatment. A more in-depth focus is dedicated to symptomatic acute pancreatitis with its peculiar findings at imaging (ultrasound, computed tomography, and magnetic resonance imaging).

Notes

Compliance with ethical standards

Funding

This research did not receive a specific grant from funding agency in the public, commercial, or non-profit sectors.

Conflict of interest

Alfredo Addeo has received research funding from Boehringer Ingelheim. He has played a consulting or advisory role in relationship with MSD, Bristol-Myers Squibb, Roche, Pfizer, Takaeda AstraZeneca and Boehringer Ingelheim. Michele Porcu, Cinzia Solinas, Cristina Migali, Angelo Battaglia, Marina Schena, Karen Willard-Gallo and Luca Saba declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

Patients consent for figure publication

All patients whose imaging pictures are present in this manuscript gave their consent for the publication.

References

  1. 1.
    Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):165.  https://doi.org/10.1038/s12276-018-0191-1.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–80.  https://doi.org/10.1038/s41571-019-0218-0.CrossRefPubMedGoogle Scholar
  3. 3.
    Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31(6):965–73.  https://doi.org/10.1038/s41379-018-0013-y.CrossRefPubMedGoogle Scholar
  4. 4.
    Grover S, Rahma OE, Hashemi N, Lim RM. Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management. Am Soc Clin Oncol Educ Book. 2018;38:13–9.  https://doi.org/10.1200/EDBK_100013.Review.CrossRefPubMedGoogle Scholar
  5. 5.
    Porcu M, De Silva P, Solinas C, et al. Immunotherapy associated pulmonary toxicity: biology behind clinical and radiologic features. Cancers. 2019;11(3):305.  https://doi.org/10.3390/cancers11030305.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709–17.  https://doi.org/10.1200/JCO.2016.68.2005.CrossRefPubMedGoogle Scholar
  7. 7.
    Zhou W, Huang Y, Lai J, Lu J, Feely M, Liu X. Anti-inflammatory biologics and anti-tumoral immune therapies-associated colitis: a focused review of literature. Gastroenterology Res. 2018;11(3):174–88.  https://doi.org/10.14740/gr1041w.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Solinas C, Porcu M, De Silva P, Musi M, Aspeslagh S, Scartozzi M, et al. Cancer immunotherapy-associated hypophysitis. Semin Oncol. 2018;45(3):181–6.  https://doi.org/10.1053/j.seminoncol.2018.09.002.CrossRefPubMedGoogle Scholar
  9. 9.
    Solinas C, Porcu M, Hlavata Z, De Silva P, Puzzoni M, Willard-Gallo K, et al. Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. Crit Rev Oncol Hematol. 2017;120:13–211.  https://doi.org/10.1016/j.critrevonc.2017.09.017.CrossRefPubMedGoogle Scholar
  10. 10.
    Porcu M, Solinas C, Garofalo P, de Azambuja E, Scartozzi M, Willard-Gallo K, et al. Radiologic evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going? Crit Rev Oncol Hematol. 2018;126:135–44.  https://doi.org/10.1016/j.critrevonc.2018.03.026.CrossRefPubMedGoogle Scholar
  11. 11.
    Hlavata Z, Solinas C, De Silva P, Porcu M, Saba L, Willard-Gallo K, et al. The abscopal effect in the era of cancer immunotherapy: a spontaneous synergism boosting anti-tumor immunity? Target Oncol. 2018;13(2):113–23.  https://doi.org/10.1007/s11523-018-0556-3.CrossRefPubMedGoogle Scholar
  12. 12.
    Widmann G, Nguyen VA, Plaickner J, Jaschke W. Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy. Curr Radiol Rep. 2016;5(11):59.  https://doi.org/10.1007/s40134-017-0256-2.CrossRefPubMedGoogle Scholar
  13. 13.
    Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3(10):1185–92.  https://doi.org/10.1158/2326-6066.CIR-15-0102.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, et al. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer. 2019;7(1):31.  https://doi.org/10.1186/s40425-019-0502-7.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58–67.  https://doi.org/10.1182/blood-2017-06-741033.CrossRefPubMedGoogle Scholar
  16. 16.
    Solinas C, Aiello M, Gu-Trantien C, De Silva P, Migliori E, Willard-Gallo K, et al. Targeting PD-1 in cancer: biological insights with a focus on breast cancer. Crit Rev Oncol Hematol. 2019;142:35–433.  https://doi.org/10.1016/j.critrevonc.2019.07.011.CrossRefPubMedGoogle Scholar
  17. 17.
    NCCN guidelines 2019 - Management of Immune Checkpoint Inhibitor-Related Toxicities, Version 2.2019. https://www.nccn.org/professionals/physician_gls/default.aspx#supportive. Accessed 8 Apr 2019.
  18. 18.
    Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119-iv142. doi: 10.1093/annonc/mdx225CrossRefGoogle Scholar
  19. 19.
    Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf Accessed 27 Nov 2017.
  20. 20.
    Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10(10):588–98.  https://doi.org/10.1038/nrclinonc.2013.153.CrossRefPubMedGoogle Scholar
  21. 21.
    Wang GX, Kurra V, Gainor JF, Sullivan RJ, Flaherty KT, Lee SI, et al. Immune checkpoint inhibitor cancer therapy: spectrum of imaging findings. Radiographics. 2017;37(7):2132–44.  https://doi.org/10.1148/rg.2017170085.CrossRefPubMedGoogle Scholar
  22. 22.
    Yoneda S, Imagawa A, Hosokawa Y, Baden MY, Kimura T, Uno S, et al. T-Lymphocyte Infiltration to islets in the pancreas of a patient who developed type 1 diabetes after administration of immune checkpoint inhibitors. Diabetes Care. 2019;42(7):e116–e11818.  https://doi.org/10.2337/dc18-2518.CrossRefPubMedGoogle Scholar
  23. 23.
    George J, Bajaj D, Sankaramangalam K, Yoo JW, Joshi NS, Gettinger S, et al. Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: a systematic review and meta-analysis. Pancreatology. 2019;19(4):587–94.  https://doi.org/10.1016/j.pan.2019.04.015.CrossRefPubMedGoogle Scholar
  24. 24.
    Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_4.03.xlsx Accessed 14 June 2010.
  25. 25.
    Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471–80.  https://doi.org/10.2337/dbi18-0002.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Eshet Y, Baruch EN, Shapira-Frommer R, Steinberg-Silman Y, Kuznetsov T, Ben-Betzalel G, et al. Clinical significance of pancreatic atrophy induced by immune-checkpoint inhibitors: a case-control study. Cancer Immunol Res. 2018;6(12):1453–8.  https://doi.org/10.1158/2326-6066.CIR-17-0659.CrossRefPubMedGoogle Scholar
  27. 27.
    El Majzoub I, Qdaisat A, Thein KZ, Win MA, Han MM, Jacobson K, et al. Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center. Ann Emerg Med. 2019;73(1):79–877.  https://doi.org/10.1016/j.annemergmed.2018.04.019.CrossRefPubMedGoogle Scholar
  28. 28.
    Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49.  https://doi.org/10.3389/fphar.2017.00049.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB. Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy. 2015;35(10):963–76.  https://doi.org/10.1002/phar.1643.CrossRefPubMedGoogle Scholar
  30. 30.
    Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33(18):2092–9.  https://doi.org/10.1200/JCO.2014.60.0379.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–48.  https://doi.org/10.1016/j.ejca.2015.11.016.CrossRefPubMedGoogle Scholar
  32. 32.
    Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015.  https://doi.org/10.14694/EdBook_AM.2015.35.76 CrossRefPubMedGoogle Scholar
  33. 33.
    Friedman CF, Clark V, Raikhel AV, et al. Thinking Critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab + ipilimumab. J Natl Cancer Inst. 2016;109(4):djw260. doi:10.1093/jnci/djw260CrossRefGoogle Scholar
  34. 34.
    Kiriyama S, Gabata T, Takada T, Hirata K, Yoshida M, Mayumi T, et al. New diagnostic criteria of acute pancreatitis. J Hepatobiliary Pancreat Sci. 2010;17(1):24–36.  https://doi.org/10.1007/s00534-009-0214-3.CrossRefPubMedGoogle Scholar
  35. 35.
    Johnson CD, Besselink MG, Carter R. Acute pancreatitis. BMJ. 2014;349:g4859.  https://doi.org/10.1136/bmj.g4859.CrossRefPubMedGoogle Scholar
  36. 36.
    Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102–11. doi: 10.1136/gutjnl-2012–302779Google Scholar
  37. 37.
    Petrov MS, Shanbhag S, Chakraborty M, Phillips AR, Windsor JA. Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis. Gastroenterology. 2010;139(3):813–20.  https://doi.org/10.1053/j.gastro.2010.06.010.CrossRefPubMedGoogle Scholar
  38. 38.
    Busireddy KK, AlObaidy M, Ramalho M, et al. Pancreatitis-imaging approach. World J Gastrointest Pathophysiol. 2014;5(3):252–70.  https://doi.org/10.4291/wjgp.v5.i3.252.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Bollen TL. Acute pancreatitis: international classification and nomenclature. Clin Radiol. 2016;71(2):121–33.  https://doi.org/10.1016/j.crad.2015.09.013.CrossRefPubMedGoogle Scholar
  40. 40.
    Foster BR, Jensen KK, Bakis G, Shaaban AM, Coakley FV. Revised atlanta classification for acute pancreatitis: a pictorial essay. Radiographics. 2016;36(3):675–87.  https://doi.org/10.1148/rg.2016150097.CrossRefPubMedGoogle Scholar
  41. 41.
    Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics. 2015;35(2):424–37.  https://doi.org/10.1148/rg.352140121.CrossRefPubMedGoogle Scholar
  42. 42.
    Dehghani L, Mikail N, Kramkimel N, Soyer P, Lebtahi R, Mallone R, et al. Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment. Eur J Cancer. 2018;104:243–6.  https://doi.org/10.1016/j.ejca.2018.09.014.CrossRefPubMedGoogle Scholar
  43. 43.
    Thoeni RF. The revised Atlanta classification of acute pancreatitis: its importance for the radiologist and its effect on treatment. Radiology. 2012;262(3):751–64.  https://doi.org/10.1148/radiol.11110947.CrossRefPubMedGoogle Scholar
  44. 44.
    Badea R. Ultrasonography of acute pancreatitis—an essay in images. Rom J Gastroenterol. 2005;14(1):83–9.PubMedGoogle Scholar
  45. 45.
    Baker ME, Nelson RC, Rosen MP, Blake MA, Cash BD, Hindman NM, et al. ACR Appropriateness criteria® acute pancreatitis. Ultrasound Q. 2014;30(4):267–73.  https://doi.org/10.1097/RUQ.0000000000000099.CrossRefPubMedGoogle Scholar
  46. 46.
    Drake LM, Anis M, Lawrence C. Accuracy of magnetic resonance cholangiopancreatography in identifying pancreatic duct disruption. J Clin Gastroenterol. 2012;46(8):696–9.  https://doi.org/10.1097/MCG.0b013e31825003b3.CrossRefPubMedGoogle Scholar
  47. 47.
    Manikkavasakar S, AlObaidy M, Busireddy KK, et al. Magnetic resonance imaging of pancreatitis: an update. World J Gastroenterol. 2014;20(40):14760–77.  https://doi.org/10.3748/wjg.v20.i40.14760.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Xiao B, Zhang XM. Magnetic resonance imaging for acute pancreatitis. World J Radiol. 2010;2(8):298–308.  https://doi.org/10.4329/wjr.v2.i8.298.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Barral M, Taouli B, Guiu B, Koh DM, Luciani A, Manfredi R, et al. Diffusion-weighted MR imaging of the pancreas: current status and recommendations. Radiology. 2015;274(1):45–63.  https://doi.org/10.1148/radiol.14130778.CrossRefPubMedGoogle Scholar
  50. 50.
    Balci NC, Alkaade S, Magas L, Momtahen AJ, Burton FR. Suspected chronic pancreatitis with normal MRCP: findings on MRI in correlation with secretin MRCP. J Magn Reson Imaging. 2008;27(1):125–31.CrossRefGoogle Scholar
  51. 51.
    Choueiri NE, Balci NC, Alkaade S, Burton FR. Advanced imaging of chronic pancreatitis. Curr Gastroenterol Rep. 2010;12(2):114–20.  https://doi.org/10.1007/s11894-010-0093-4.CrossRefPubMedGoogle Scholar
  52. 52.
    Perez-Johnston R, Sainani NI, Sahani DV. Imaging of chronic pancreatitis (including groove and autoimmune pancreatitis). Radiol Clin North Am. 2012;50(3):447–66.  https://doi.org/10.1016/j.rcl.2012.03.005.CrossRefPubMedGoogle Scholar
  53. 53.
    Majumder S, Takahashi N, Chari ST. Autoimmune pancreatitis. Dig Dis Sci. 2017;62(7):1762–9.  https://doi.org/10.1007/s10620-017-4541-y.CrossRefPubMedGoogle Scholar
  54. 54.
    Zhang L, Chari S, Smyrk TC, Deshpande V, Klöppel G, Kojima M, et al. Autoimmune pancreatitis (AIP) type 1 and type 2: an international consensus study on histopathologic diagnostic criteria. Pancreas. 2011;40(8):1172–9.  https://doi.org/10.1097/MPA.0b013e318233bec5.CrossRefPubMedGoogle Scholar
  55. 55.
    Madhani K, Farrell JJ. Autoimmune pancreatitis: an update on diagnosis and management. Gastroenterol Clin North Am. 2016;45(1):29–43.  https://doi.org/10.1016/j.gtc.2015.10.005.CrossRefPubMedGoogle Scholar
  56. 56.
    Madhani K, Farrell JJ. Management of autoimmune pancreatitis. Gastrointest Endosc Clin N Am. 2018;28(4):493–519.  https://doi.org/10.1016/j.giec.2018.05.002.CrossRefPubMedGoogle Scholar
  57. 57.
    Lee LK, Sahani DV. Autoimmune pancreatitis in the context of IgG4-related disease: review of imaging findings. World J Gastroenterol. 2014;20(41):15177–89.  https://doi.org/10.3748/wjg.v20.i41.15177.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, et al. International association of pancreatology. international consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the international association of pancreatology. Pancreas. 2011;40(3):352–8. doi: 10.1097/MPA.0b013e3182142fd2CrossRefGoogle Scholar
  59. 59.
    Dickerson LD, Farooq A, Bano F, Kleeff J, Baron R, Raraty M, et al. Differentiation of autoimmune pancreatitis from pancreatic cancer remains challenging. World J Surg. 2019;43(6):1604–11.  https://doi.org/10.1007/s00268-019-04928-w.CrossRefPubMedGoogle Scholar
  60. 60.
    Saba L, Biswas M, Kuppili V, Cuadrado Godia E, Suri HS, Edla DR, et al. The present and future of deep learning in radiology. Eur J Radiol. 2019;114:14–24.  https://doi.org/10.1016/j.ejrad.2019.02.038.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of RadiologyAzienda Ospedaliera Universitaria Di CagliariMonserrato, CagliariItaly
  2. 2.Azienda AUSL, Regional Hospital of AostaAostaItaly
  3. 3.AIFARomeItaly
  4. 4.IRCSS SDNNaplesItaly
  5. 5.Oncology DepartmentUniversity Hospital of GenevaGenevaSwitzerland
  6. 6.Molecular Immunology UnitInstitut Jules BordetBrusselsBelgium

Personalised recommendations